iCo Therapeutics Announces Third Quarter 2017 Financial Results
November 28, 2017, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
November 28, 2017, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
November 22, 2017, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
September 7, 2017, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
August 29, 2017, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
August 4, 2017, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
June 30, 2017, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB:
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB:
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB:
April 19, 2017, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)